ReviewMedicina (Kaunas, Lithuania)2022
Modifiable and Non-Modifiable Risk Factors for the Development of Non-Hereditary Pancreatic Cancer.
Review in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?International journal of molecular sciences · 2026Pooled it
- From radiomics to transformers in pancreatic cancer detection and prognosis.Frontiers in medicine · 2025Pooled it
- Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids.Cells · 2026Review
- Distinct Inflammatory and Dissemination Signatures Defined by Macrophage Migration Inhibitory Factor (MIF), Interleukin-8 (IL-8/CXCL8), and Stem Cell Factor (SCF) in Pancreatic Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Understanding Cancer Health Disparities.Cancers · 2026Review
- Anticancer potential of dietary fiber for colorectal carcinoma: a narrative review.Annals of medicine · 2025Review
- Beyond Biology: Uncovering Structural and Sociocultural Predictors of Breast Cancer Incidence Worldwide.Current oncology (Toronto, Ont.) · 2025Article
- Pancreatic cancer: a persistently challenging prognosis - a single center three-year retrospective study.Medicine and pharmacy reports · 2025Article
- Enhancing cancer risk awareness and screening management through artificial intelligence: a narrative review.Frontiers in oncology · 2025Review
- Impact of SGLT2 Inhibitors on Tumor Development Risk in Type 2 Diabetes: A Retrospective Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Microbiome and metabolome analysis in smoking and non-smoking pancreatic ductal adenocarcinoma patients.BMC microbiology · 2024Article
- Pigment Epithelial-Derived Factor in Pancreatic and Liver Cancers-From Inflammation to Cancer.Biomedicines · 2024Review
- Childhood and adulthood passive and active smoking, and the ABO group as risk factors for pancreatic cancer in women.United European gastroenterology journal · 2024Article
- CENPN contributes to pancreatic carcinoma progression through the MDM2-mediated p53 signaling pathway.Archives of medical science : AMS · 2024Article
- Incidence and risk factors of pancreatic cancer during 15 years follow-up in the Golestan Cohort Study in Iran.PloS one · 2024Article
- Pancreatic Ductal Adenocarcinoma and Nutrition: Exploring the Role of Diet and Gut Health.Nutrients · 2023Review
- Editorial for the Special Issue "Acute and Chronic Pancreatitis, Pancreatic Malignancies".Medicina (Kaunas, Lithuania) · 2023Article
- Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells.International journal of molecular sciences · 2023Article
- Smoking and pancreatic cancer: a sex-specific analysis in the Multiethnic Cohort study.Cancer causes & control : CCC · 2023Article
- Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is becoming an increasing healthcare concern. Though it is a 14th most common cancer worldwide, its incidence is steadily rising. Results of currently available therapies are still not satisfactory. Therefore, great attention should be put on the identification and reduction of risk factors for pancreatic cancer. A thorough up-to-date review of available data on the impact of well-established and novel risk factors of pancreatic cancer development have been performed. Several risk factors associated with lifestyle have significant impact on the risk of pancreatic cancer (i.e., smoking, obesity, alcohol consumption). Physicians should also be aware of the novel findings suggesting increasing role of microbiome, including viral and bacterial infections, in the development of pancreatic cancer. A growing body of evidence suggest also an increased risk during certain occupational exposures. In general, lifestyle seems to be a major contributor in the development of pancreatic cancer. Special attention should be given to individuals with a vicious cluster consisting of metabolic syndrome, tobacco smoking and alcohol consumption. Physicians should urge patients to comply to healthy diet, cessation of smoking and moderation of alcohol consumption, which may halve pancreatic cancer incidence. Further studies are warranted to explore the potential use of therapeutic approach on novel risk factors (e.g., microbiome).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.